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I nstruments that measure clinical benefit are useful tosupport policy decision making. They can help to assess thevalue of new treatments andmay provide insights to informthe design of future clinical trials.1–3 The European Society
for Medical Oncology (ESMO) developed a valuable tool to
assess the magnitude of clinical benefit from new cancer therapies
– the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS)
– that has been validated and proven reproducible in solid tumor
oncology.4,5 This value framework is currently incorporated into
ESMO’s clinical practice guidelines and is being used to inform
health technology assessment processes.1,2
The European Hematology Association (EHA) has observed
the development of the ESMO-MCBS with interest, since no
oncology frameworks have yet been validated for assessing
treatments for hematologic malignancies. Given the increasing
number of treatments available for these types of malignancy,
that often target small, well-defined patient populations,
availability of an appropriate validated assessment for hemato-
logic malignancies is of pressing importance. Consequently,
experts from EHA and ESMO tested the latest version of ESMO-
MCBS (version 1.1) in several hematologic malignancies, and
their findings have recently been published.6
Experts from relevant EHA Scientific Working Groups
identified and graded 80 studies of recently approved treatments
for hematologic malignancies using the ESMO-MCBS version
1.1 forms.5,6 Their gradings were then reviewed by the ESMO-
MCBS Working Group to ensure applicability and correctness.
The hematologic malignancies considered included acute lym-
phoblastic leukemia (ALL), acute myeloid leukemia (AML),
chronic lymphocytic leukemia (CLL), chronic myeloid leukemia
(CML), Hodgkin and non-Hodgkin lymphomas, multiple
myeloma (MM) and myelodysplastic syndromes (MDS). For
each of these diseases, the scoreability of the studies and the
reasonableness of the derived scores were evaluated so that any
shortcomings in the current version of ESMO-MCBS, when
applied to each hematological malignancy, could be identified.
Clinical benefit was graded for treatments with curative intent
and for treatments with non-curative intent.
The ESMO-MCBS version 1.1 was widely applicable to the
overwhelming majority of studies analyzed by EHA experts. Of
the 80 studies analyzed, 72 (90%) could be scored, and the scores
generated were generally considered to correspond with expert
assessment of the magnitude of clinical benefit obtained for the
treatments under evaluation. This is encouraging but suggests
that more work is needed to increase this further.
A key aim of this project was to probe the ESMO-MCBS more
deeply, to identify key differences between sold tumors and
hematological malignancies in order to isolate the most
important shortcomings that would need to be addressed and
amended in order to develop a version that is applicable more
robustly to the full spectrum of hematologic malignancies. Due to
the high degree of cooperation that existed between the scientific
leadership of the ESMO-Magnitude of Clinical Benefit Working
Group and the EuropeanHematology Association over the past 2
years, this project has resulted in the completion of this work,
which has recently been published in ESMO Open.6
Some shortcomings in the capacity ofESMO-MCBS tograde the
magnitude of clinical benefit appropriately were identified for
almost all types of hematological malignancies (with the exception
of AML); these shortcomings are summarized in Table 1.
This critical accomplishment is now facilitating thenext phase of
this ongoing collaboration between our organizations, the
development of a robustly validated version of the ESMO-MCBS
for hematological malignancies: ESMO-MCBS:H. This process is
underway: a draft version of ESMO-MCBS:H has been prepared
which will undergo scientific review, statistical validation,
extensive field testing and a process of expert peer review for
reasonableness. These methodological stringencies are essential to
meet the standards of “accountability for reasonableness”7 that
underlie the integrity of this endeavorwhich is critical to bothEHA
and ESMO and to the use of the tool in public health policy.
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We look forward to this important challenge with the secure
knowledge that we now have an established track record of
tremendous cooperation. We believe that the ESMO-MCBS:H
will make a major contribution to the word of malignant
hematology.
Conclusions
The ESMO-MCBS version 1.1 is widely applicable to studies of
recently approved treatments for hematological malignancies
analyzed by EHA experts. However, a number of modifications
are necessary to enable hematological malignancies to be
validated within the ESMO-MCBS framework. Based on the
findings of this EHA analysis, EHA and ESMO are committed to
develop a version of the scale that is robustly validated to grade
studies of new treatments for hematological malignancies.
Collaboration between these organizations is ongoing in order
to achieve this in a timely manner.
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Table 1
Amendments Identified for ESMO-MCBS Version 1.1 to Incorporate Hematologic Malignancies.
• Incorporate a way to grade single-arm studies evaluating curative treatments, such as CAR T-cell salvage therapy.
• Provide a mechanism for incorporating substantial interim survival gains for conditions with very long PFS or OS (eg, CLL, CML, indolent lymphoma and MM) when median
survival has not yet been reached in the control arm.
• Improve the valuation of treatments that provide a strong, late gain in PFS when there is no plateauing of the PFS curve.
• Incorporate deep and complete cytogenic responses and major molecular responses as surrogates for survival in CML.
• Allow the grading of non-inferiority studies that evaluate response rates.
• Provide a means of incorporating QOL benefit in studies evaluating response rate as a primary outcome and QOL as a secondary outcome.
CAR = chimeric antigen receptor, CLL = chronic lymphocytic leukemia, CML = chronic myeloid leukemia, MM = multiple myeloma, PFS = progression-free survival, OS = overall survival, QOL = quality of life.
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